





Programa de apoio à prescrição antibiótica: o que estamos a fazer Resultados nacionais do PPCIRA

<u>José Artur Paiva</u>, Maria Goreti Silva, Paulo André Fernandes, Anabela Coelho, José Alexandre Diniz, Francisco George



Where were we in 2011-2012? Before PPCIRA.....

The situation in 2012



- High rate of health care associated infections
- The highest carbapenem and vancomycin consumption in Europe
- High quinolone consumption in the community setting
- The highest rate of methicillin resistance among Staph. aureus
- Endemic XDR Acinetobacter spp
- Rising level of ESBL producing Enterobacteriaceae
- Outbreaks of carbapenem resistant Enterobacteriaceae

Primeira KPC em Portugal foi identificada numa unidade pediátrica do Hospital de Santa Maria, em 2009

(8 anos após isolamento seminal em North Carolina)

RPDI

Setembro > Dezembro 2012 / Vol. 8 > N.º 3

127

ARTIGO ORIGINAL / ORIGINAL ARTICLE

Carbapenemase KPC-3 em estirpes de Klebsiella pneumoniae numa unidade hospitalar

Klebsiella pneumoniae producing carbapenemase KPC-3 identified in hospital wards

/F. Calisto¹ / C. Caneiras¹ / S. Cerqueira¹ / L. Lito² / J. Melo-Cristino^{2,3} / A. Duarte¹

- ¹ iMed.UL-Research Institute for Medicines and Pharmaceuticals Sciences. Laboratório de Microbiologia, Faculdade de Farmácia, Universidade de Lisboa
- ² Centro Hospitalar Lisboa Norte, Lisboa, Portugal
- ³ Instituto de Microbiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa

/ Resumo

A emergência e disseminação global de ${\it Enterobacteriaceae}$ resistentes aos carbapenemos é uma ameaça à saúde pública, pois estão associadas a altas taxas de morbilidade e mortalidade. Este estudo teve como objectivo caracterizar o gene $bla_{{\it KPC-3}}$, o seu ambiente genético e outras resistências associadas, em bactérias resistentes e com reduzida susceptibilidade aos carbapenemos no ${\it Centro}$ Hospitalar de Lisboa Norte, EPE.

The fight against the situation Direção-Geral da Saúde



NATIONAL PROGRAM **OF INFECTION** CONTROL



NATIONAL PROGRAM ON PREVENTION OF **ANTIMICROBIAL** RESISTANCE

2008

1999


Weaknesses and threats



- Low level of integration and synergy of the several processes; no holistic vision; too many process leaders
- Understaffing underpowerment of the central and peripheral structures
- Absence of focus in the most relevant issues: MRSA, CRE, carbapenems, quinolones, Standard precautions campaign
- Problems of data sharing among state institutions and of data feedback to the providers
- Difficulties in implementing a collaborative model, increasing capacity building and maximizing participation.
- Reimbursement system not reflecting the indicators and targets and not boosting motivation

Low perception that antimicrobial use is the driver of antimicrobial resistance





Towards pan-resistance



- A total of 26,4% of all *K. pneumoniae* isolates had AST results for polymyxins. A total of 8.8% of the isolates were resistant to polymyxins. A majority of these originated from Greece, Italy, Romania and Hungary.
- ❖ 26% of all isolates were tested for both carbapenem and polymyxins. Out of these, 6.6% were resistant to both polymyxins and carbapenems.

A majority of these isolates were reported from Greece, Italy and Romania.

Around 6% of all *K. pneumoniae* isolates were resistant to all classes under EARS-Net surveillance.

PPCIRA: one leadership



OF INFECTION CONTROL

1999

+

NATIONAL PROGRAM ON PREVENTION OF ANTIMICROBIAL RESISTANCE

2008

MINISTÉRIO DA SAÚDE

Gabinete do Secretário de Estado Adjunto do Ministro da Saúde

Despacho n.º 2902/2013

PROGRAM ON PREVENTION AND CONTROL OF INFECTION AND ANTIMICROBIAL RESISTANCE

8 Feb 2013



STANDARD PRECAUTIONS CAMPAIGN

To reduce the emergence of antimicrobial resistance

Epidemiological surveillance

To reduce the incidence of resistant bacteria

PPCIRA "bundles"



- Hand hygiene
- ✓ Adequate use of gloves
- Patient/clinical environmental hygiene
- ✓ "Anti-MRSA" policy
- ✓ Surgical antibiotic prophylaxis for no more than 24 h
- ✓ Duration of antibiotic duration limited to 7 days (with exceptions)
- Reduction of quinolone and carbapenem prescription
- Antimicrobial stewardship program in the first 96 h

Comunity Bundle

- ✓ Hand hygiene
- ✓ Adequate use of gloves
- Patient/Clinical environmental hygiene
- ✓ Compliance with the vaccination program
- Adquate tretment of wounds
- Reduction in the prescription of quinolones
- Guideline for the treatment of RTI
- ✓ Guideline for the treatment of UTI
- ✓ Antimicrobial stewardship program

Hospital Bundle

Education and Pedagogy



- "Train the trainers" course
- In all RHA (7 health regions)
- Topics: strategy, implementation and science
- Two modules, hospital and ambulatory, in two consecutive days
- 4 trainers per course; a total of 8 trainers
- In October 2014, more than 600 doctors and nurses were trained as trainers

Adhesion to the main interventions




	Launching	2012	2014
Epidemiological surveillance of antimcrobial resistance (Microbiology Lab)	Guideline NRL/DGH 21 February 2013	22	70
Epidemiological surveillance of at least one of the HAI	Law 15423/2013 18 November 2013		85%
Antimicrobial Stewardship Program	Law 15423/2013 18 November 2013	0	40% hospitals
Standard Precautions Campaign	5 May 2014	-	70% hospitals 24% PCC

September 2014 PPCIRA /DGH

Best antimicrobial selection Spireca-Geral



Treat adequately & with the least possible collateral damage



emergence of resistance selection of pathogenic organisms (CD) drug adverse events

John Locke's proviso BG DG Direção-Ger





Morality of the use of scarce resources

 One is allowed to take something from nature and make it own property only where there is enough and as good left in common for others

Antibiotics are scarce resources

Antibiotic dilemma



Inappropriate antibiotic therapy is linked to increased mortality

Overuse of antibiotics is linked to increased emergence of resistance

The expectation of the patient to maximum treatment and shared decisions

The right of future patients to effective treatment

Justice between persons and between generations

Education on the prudent use of antibiotics

PRESCRIBERS of ANTIBIOTICS




Medical doctors, nurses, midwives, dentists, veterinarians > 30 yPOSTGRADUATE EDUCATION intervention strategies

CHANGING BEHAVIOR

All doctors, from all specialties, prescribe antibiotics, unlike other drugs

Education, education, education

Education but please also create
 A DEDICATED PROCESS / TEAM





ANTIMICROBIAL STEWARDSHIP PROGRAMME

Strategies and Prescription Pattern



MULTIDISCIPLINARY ANTIMICROBIAL STEWARDSHIP TEAM: Physician champion, microbiologist, pharmacist, ICP nurse

Restrictive strategies

produce quicker results

but not sustainable



take longer to impact

but the effect lasts longer



Interaction, communication and commitment



Microbiology
Laboratory
/ Clinicians Interaction

Infectious Disease or Antibiotic Champion / Clinicians Interaction

Director and Head Nurse


At a Service/Department level

At an individual level

A marriage of infection control and antimicrobial management



The successful implementation of ASP and ICP complement eachother in limiting the number of infections caused by MDR pathogens



Synergistic processes

Antimicrobial stewardship interventions



- No antibiotics when there is no bacterial infection
- Avoid antibiotics with high collateral damage
- Reduce quinolone and carbapenem use (and cephalosporins)
- Promote amox/clav and pip/taz use in some infections caused by ESBL+ Enterobacteriaceae
- Targeted / Escalation therapy in low risk patients
- De-escalation therapy in high risk patients
- Use PK/PD concepts
- Limit surgical prophylaxis to not more than 24 hours
- Reduce duration of antimicrobial therapy

ASP metrics selection (3 domains)



Domain	Metric	Description*
Consumption	Expenditures	-Dollars spent from purchased, dispensed or administered data
	Grams	-Grams used from purchased, dispensed or administered data
	Defined Daily Doses (DDD)	-Grams used (as above) divided by WHO** approved DDD values
	Days Of Therapy (DOT)	-Number of days that patient receives at least one dose of an antibiotic summed for each antibiotic
	Length of Therapy (LOT) "treatment period"	-Number of days that patient receives therapy regardless of number of different drugs or doses
Patient Outcomes	Health care associated infections	-% of patients with infection -ASP intervention/acceptance rates
Resistance	Antibiotic resistant organisms	-% of patients with resistant organism(s) -Antibiogram


• Common denominator: 1000 patient days,




Where are we? PPCIRA results

Antibiotic consumption the ambulatory setting






Reduction of quinolone consumption in the ambulatory setting Consumption in the ambulatory setting



Reduction of antibiotic consumption in portuguese hospitals 2012-2013



Consumo anual de antibacterianos nos hospitais do SNS (DDD)



GUIDELINES:


- Duration of antibiotic treatment
- Treatment of UTI
- Surgical antibiotic prophylaxis

stewardship **Antibiotic**

Reduction of antibiotic consumption **B** DGS desde 1899 in the hospital setting



Hospital antibiotic consumption in the 1st semester of the year




e quinolonas (DDD) Carbapenemes

Feedbacking data to hospitals

Reduction of the rate of Staphylococcus aureus resistance to methicillin (MRSA)



% of the invasive *Staph aureus* isolates resistant to methicillin



Acinetobacter spp resistant to



	2012		2013				
Country	N		(95% CI)	N		(95% CI)	
Finland			()	35		(0-10)	
Norway	25		(0-14)	36		(0-10)	
Netherlands	67		(2-15)	65		(0-8)	
Denmark	64		(4-19)	61		(0-9)	
United Kingdom	80		(0-9)	149		(0-6)	
Ireland			()	85		(0-8)	
Czech Republic			()	91		(1-11)	
Sweden			()	72	5.6	(2-14)	
France	389		(2-6)	406	5.9	(4-9)	
Austria			()	51	7.8	(2-19)	
Germany	121		(3-13)	173	9.2	(5-15)	
Slovenia	25		(9-45)	25	24	(9-45)	
Slovakia			()	142	45.8	(37-54)	
Poland	209	38.3	(32-45)	189	49.7	(42-57)	
Hungary	418	48.1	(43-53)	481	50.1	(46-55)	
Bulgaria	58	60.3	(47-73)	89	59.6	(49-70)	
Cyprus	23	56.5	(34-77)	33	60.6	(42-77)	
Portugal	168	79.2	(72-85)	229	69	(63-75)	
Romania	54	81.5	(69-91)	137	85.4	(78-91)	
Croatia			()	114	89.5	(82-94)	
Greece	1254	87.8	(86-90)	848	90.6	(88-92)	
Iceland	2	#	(#-#)	-		()	
Belgium			()	3	#	(#-#)	
Luxembourg	5	#	(#-#)	1	#	(#-#)	
Malta	6	#	(# #)	7	#	(#-#)	

CRE alert surveillance system 1.8% of all *Enterobacteriaceae*



GES-type 5 KPC-type 195 VIM-type 9 KPC-type, GES-type 2 NDM-type 1 Subtotal 212 (40%) Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species 23 Probable impermeability mechanism 3 Probable impermeability mechanism 3 Subtotal 240 (45,3%) Isolates susceptible to the carbapenems 76		
GES-type	Mechanisms of carbapenem resistance	Number of isolates (%)
KPC-type VIM-type FPC-type, GES-type FPC-type, GES-type FPC-type, GES-type FPC-type FPC-type, GES-type FPC-type FPC-type, GES-type FPC-type, GES-t	Production of acquired carbapenemase	
VIM-type 9 KPC-type, GES-type 2 NDM-type 1 Subtotal 212 (40%) Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species 23 Probable impermeability mechanism 3 Probable impermeability mechanism 3 Subtotal 240 (45,3%) Isolates susceptible to the carbapenems 76 Non-viable isolates 2 Subtotal 78 (14,7%)	GES-type	5
KPC-type, GES-type NDM-type Subtotal Subtotal Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species Probable impermeability mechanism Subtotal Subtotal Subtotal Subtotal 76 Non-viable isolates Subtotal Non-viable isolates Subtotal 78 (14,7%)	KPC-type	195
NDM-type 1 Subtotal 212 (40%) Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species 23 Probable impermeability mechanism 3 Probable impermeability mechanism 3 Subtotal 240 (45,3%) Isolates susceptible to the carbapenems 76 Non-viable isolates 2 Subtotal 78 (14,7%)	VIM-type	9
Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species Probable impermeability mechanism Subtotal Subtotal Subtotal 76 Non-viable isolates Subtotal Subtotal Subtotal 78 (14,7%)	KPC-type, GES-type	2
Other mechanisms ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species Probable impermeability mechanism 3 Subtotal Isolates susceptible to the carbapenems Non-viable isolates Subtotal 76 Subtotal 78 (14,7%)	NDM-type	1
ESBL and/or AmpC production associated with impermeability mechanism Imipenem resistance mechanism inherent to te species Probable impermeability mechanism Subtotal Subtotal For a susceptible to the carbapenems Non-viable isolates Subtotal To a subtotal	Subtotal	212 (40%)
impermeability mechanism Imipenem resistance mechanism inherent to te species Probable impermeability mechanism Subtotal Subtotal Formula impermeability mechanism Subtotal Subtotal Total To	Other mechanisms	
Probable impermeability mechanism Subtotal Subtotal 13 15 15 15 15 16 17 16 17 17 17 18 18 18 18 18 18 18		214
Subtotal 240 (45,3%) Isolates susceptible to the carbapenems 76 Non-viable isolates Subtotal 78 (14,7%)	Imipenem resistance mechanism inherent to te species	23
Isolates susceptible to the carbapenems 76 Non-viable isolates 2 Subtotal 78 (14,7%)	Probable impermeability mechanism	3
Non-viable isolates 2 Subtotal 78 (14,7%)	Subtotal	240 (45,3%)
Subtotal 78 (14,7%)	Isolates susceptible to the carbapenems	76
	Non-viable isolates	2
TOTAL 530	Subtotal	78 (14,7%)
	TOTAL	530



Next months.....

Antibiotic stewardship



Increase hospital coverage

Reach primary / community care and LTCF

So much easy in na ULS organization.......

Long term care and CRE



- The presence of CRE carriage has been described in a number of investigations involving patients from postacute care facilities, particularly long-term acute care hospitals
- ❖ Perez et al found that greater than 50% of patients with carbapenemresistant gram-negative organisms were admitted from postacute care facilities, suggesting that these settings may be important reservoirs for the transmission and dissemination of these organisms.
- ❖ In an investigation of 3 patients with KPC-producing CRE infection transferred to a hospital from a LTACH, active surveillance cultures from residents in the same LTACH unit as the case-patients identified CRE colonization among 49% of residents (unpublished CDC data).

Perez F, et al. J Antimicrob Chemother 2010; 65:1807–18.

HCAI in long term care institutions



GUIDELINES:

- Standard precautions
- Prevention of surgical site infection
- Prevention of chronic wound infection

	Convalescença	Média duração	Longa duração	Paliativos	Total
Infeção urinária Confirmada Provável	11 (24,4%) 11 (24,4%)	22 (19,5%) 24 (21,2%)	27 (15,2%) 34 (19,1%)	-	60 (17,5%) 69 (20,0%)
Infeção respiratória Superior Inferior	2 (4,4%) 8 (17,7%)	5 (4,4%) 20 (17,7%)	7 (3,9%) 28 (15,7%)	1 (16,6%) 2 (33,3%)	15 (4,5%) 58 (16,9%)
Infeção da pele e tecidos moles Infeção fungica	6 (13,3%)	26 (23%) 3 (2,6%)	47 (26,4%) 4 (2,2%)	3 (7,5%) -	82 (23,8%) 7 (2,0%)
Infeções gastrintestinais Infeção por <i>C. difficile</i>	2 (4,4%) 2 (4,4%)	5 (4,4%)	10 (5,6%)	-	17 (4,9%) 2 (0,6%)
Infeções oculares	2 (4,4%)	5 (4,4%)	12 (6,7%)	-	19 (5,5%)
Infeção do nariz ouvido e boca	1 (2,2%)	-	4 (2,2%)	-	5 (1,5%)
Infeção da corrente sanguínea	-	1 (0,9%)	-	-	1 (0,3%)
Síndrome febril inexplicado	<u></u>	2 (1,8%)	5 (2,8%)	-	(2,0%)
Outras	1	-	1	-	2 (0,6%)
Total	45 (10%)	113 (13,2%)	178 (10,5%)	6 (15%)	344 (11,3%)

Fontes Healthcare-Associated Infection and Antimicrobial Use in Long-Term Care Facilities, HALT 2, Inquérito de prevalência de infeção nas unidades de cuidados continuados, 2014, DGS http://www.dgs.pt/documentos-e-publicacoes/inquerito-de-prevalencia-de-infecao-e-uso-de-antimicrobianos-nas-unidades-de-cuidados-continuados-2013.aspx

PPCIRA institutional assessment



- 1. To have PPCIRA-Local Coordinating Group in accordance with 15423/2013 law
- 2. To participate in the epidemiollogical surveillance of antimicrobial resisitance, through LCG and Microbiology Labs.
- 3. To participate in the 4 epidemiological surveillance programs on HAI
- 4. To analyse institution's data on antimicrobial consumption, relating them to antimicrobial resistance patterns
- 5. To have a Antimicrobial Stewardship Program
- 6. To participate in the Standard Precautions Campaign
- 7. To reduce mean duration of antibiotic treatment course
- 8. To reduce to zero surgical antibiotic prophylaxis > 24h
- 9. To increase antibiotic free days
- 10. To reduce carbapenem consumption in hospitals
- 11. To reduce % patients that acquire colonization or infection by MDR in hospitals
- 12. To reduce hospital MRSA rate
- 13. To avoid increase in CRE rate
- 14. To reduce % of patients on antibiotic treatment for chronic wound
- 15. To reduce quinolone consumption in the ambulatory setting

Citizen's awareness Winter 2013



Sabia que tomar antibióticos tem riscos significativos?

Poucas pessoas sabem que sempre que se toma um antibiótico sem necessidade, ou não cumprindo as instruções médicas, aumenta a resistência das bactérias que deveria combater e, portanto, reduz a eficacia do antibiótico.

 Sabia que as infecções por bactérias resistentes são mais difíceis de curar e transmitem-se a outras pessoas?

As bactérias resistentes sobrevivem na presença do antibiótico e continuam a multiplicar-se, causando uma doença mais grave e mais dificil de tratar. Estas bactérias podem transmitir-se de pessoa para pessoa, quer seja directamente ou através do meio ambiente.

 Sabia que infecções causadas por virus não devem ser tratadas com antibióticos?

A maioria das infecções comuns, tais como as constipações e as gripes, são causadas por virus e não por bactérias e portanto não são curadas por antibióticos.

NÃO SE DEVE TOMAR ANTIBIÓTICOS NO CASO DE



- X CONSTIPAÇÃO
- X GRIPE
- X DOR DE GARGANTA
- X PINGO NO NARIZ
- X TOSSE SECA

Como posso saber se devo tomar um antibiótico?

Apenas o médico pode fazer o diagnóstico correcto e decidir se é necessáno receitar antibiótico e, nesse caso, qual o antibiótico aconselhado. Não deve, em caso algum, automedicar-se. Se the for prescrito um antibiótico cumpra as instruções do médico, em termos de dose, horário das tomas e duração do tratamento. Se sobrarem comprimidos no film do tratamento; devolve-os à farmácia.





LEMBRE-SE tomar antibióticos torna as bactérias resistentes AJUDE A ELIMINAR ESTE PROBLEMA





aconselhe-se com o seu médico

PRESERVE OS ANTIBIÓTICOS - CAMPANHA DE SENSIBILIZAÇÃO DO CIDADÃO -

LEMBRE-SE



NÃO ABUSE





ANTIBIÓTICOS A MAIS, SAÚDE A MENOS aconselhe-se com o seu médico

Conclusions: the problem



We still have, in our hospitals:

- High unnecessary carbapenem consumption
- High incidence of carbapenem resistant Acinetobacter spp (69%) and of XDR Acinetobacter (56%)
- High incidence of carbapenem resistant *Pseudomonas* aeruginosa (21%), although combined resistance is clearly lower (12%)
- Low but rising incidence of KPC and outbreaks of CRE

Conclusions: the response



- Create and develop an antimicrobial stewardship programm
- Make it multidisciplinary and efficient
- Costumize it to diferente services and hospitals
- Define AMS physician champions as leaders and increase the interaction with microbiology
- Make it persuasive and pedagogical
- Assure accountability, defining goals and metrics in 3 domains: decrease antibiotic consumption, hospital acquired infections and antimicrobial resistance
- Communicate results to the staff

Thanks!





ppcira@dgs.pt